European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42% AZN, -1.26% said it’s pay...
European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42% AZN, -1.26% said it’s pay...